메뉴 건너뛰기




Volumn 25, Issue 1, 2011, Pages 37-52

Oral therapies for multiple sclerosis: A review of agents in phase III development or recently approved

Author keywords

BG 12, general; Cladribine, general; Fingolimod, general; Laquinimod, general; Multiple sclerosis; Oral; Teriflunomide, general.

Indexed keywords

BETA1A INTERFERON; CLADRIBINE; CYCLOPHOSPHAMIDE; FINGOLIMOD; FUMADERM; FUMARIC ACID DIMETHYL ESTER; GAMMA INTERFERON; GLATIRAMER; INTERFERON BETA SERINE; INTERLEUKIN 10; INTERLEUKIN 1BETA; INTERLEUKIN 6; LAQUINIMOD; LEFLUNOMIDE; PLACEBO; PROSTAGLANDIN SYNTHASE; RASAGILINE; ROQUINIMEX; TERIFLUNOMIDE; TRANSCRIPTION FACTOR NRF2; TUMOR NECROSIS FACTOR ALPHA;

EID: 78649826782     PISSN: 11727047     EISSN: 11791934     Source Type: Journal    
DOI: 10.2165/11539820-000000000-00000     Document Type: Review
Times cited : (50)

References (77)
  • 2
    • 77954595101 scopus 로고    scopus 로고
    • Optimizing the benefit of multiple sclerosis therapy: The importance of treatment adherence
    • Patti F. Optimizing the benefit of multiple sclerosis therapy: the importance of treatment adherence. Patient Prefer Adherence 2010; 4: 1-9.
    • (2010) Patient Prefer Adherence , vol.4 , pp. 1-9
    • Patti, F.1
  • 3
    • 64249093467 scopus 로고    scopus 로고
    • A review of disease- modifying therapies for MS: Maximizing adherence and minimizing adverse events
    • Brandes DW, Callender T, Lathi E, et al. A review of disease- modifying therapies for MS: maximizing adherence and minimizing adverse events. Curr Med Res Opin 2009; 25: 77-92.
    • (2009) Curr Med Res Opin , vol.25 , pp. 77-92
    • Brandes, D.W.1    Callender, T.2    Lathi, E.3
  • 4
    • 65749088247 scopus 로고    scopus 로고
    • Factors that influ- ence adherence with disease-modifying therapy in MS
    • Treadaway K, Cutter G, Salter A, et al. Factors that influ- ence adherence with disease-modifying therapy in MS. J Neurol 2009; 256: 568-76.
    • (2009) J Neurol , vol.256 , pp. 568-76
    • Treadaway, K.1    Cutter, G.2    Salter, A.3
  • 5
    • 10644241482 scopus 로고    scopus 로고
    • Localized panniculitis and subsequent lipoatrophy with subcutaneous glatiramer acetate (Copaxone) injection for the treatment of multiple sclerosis
    • Soos N, Shakery K, Mrowietz U. Localized panniculitis and subsequent lipoatrophy with subcutaneous glatiramer acetate (Copaxone) injection for the treatment of multiple sclerosis. Am J Clin Dermatol 2004; 5: 357-9.
    • (2004) Am J Clin Dermatol , vol.5 , pp. 357-9
    • Soos, N.1    Shakery, K.2    Mrowietz, U.3
  • 6
    • 76149083915 scopus 로고    scopus 로고
    • A placebo-controlled trial of oral cladribine for relapsing multiple sclerosis
    • Giovannoni G, Comi G, Cook S, et al. A placebo-controlled trial of oral cladribine for relapsing multiple sclerosis. N Engl J Med 2010; 362: 416-26.
    • (2010) N Engl J Med , vol.362 , pp. 416-26
    • Giovannoni, G.1    Comi, G.2    Cook, S.3
  • 7
    • 76149093586 scopus 로고    scopus 로고
    • A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis
    • Kappos L, Radue EW, O'Connor P, et al. A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis. N Engl J Med 2010; 362: 387-401.
    • (2010) N Engl J Med , vol.362 , pp. 387-401
    • Kappos, L.1    Radue, E.W.2    O'Connor, P.3
  • 8
    • 76149140914 scopus 로고    scopus 로고
    • Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis
    • Cohen J, Barkhof F, Comi G, et al. Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis. N Engl J Med 2010; 362: 402-15.
    • (2010) N Engl J Med , vol.362 , pp. 402-15
    • Cohen, J.1    Barkhof, F.2    Comi, G.3
  • 9
    • 78649839271 scopus 로고    scopus 로고
    • A placebo- controlled phase III trial (TEMSO) of oral teriflunomide in relapsing multiple sclerosis: Clinical efficacy and safety outcomes [abstract]
    • O'Connor P, Wolinsky J, Confavreux C, et al. A placebo- controlled phase III trial (TEMSO) of oral teriflunomide in relapsing multiple sclerosis: clinical efficacy and safety outcomes [abstract]. Mult Scler 2010; 16: S23.79.
    • (2010) Mult Scler , vol.16
    • O'Connor, P.1    Wolinsky, J.2    Confavreux, C.3
  • 10
    • 27944443692 scopus 로고    scopus 로고
    • Cladribine for multiple sclerosis: Review and current status
    • Sipe JC. Cladribine for multiple sclerosis: review and current status. Expert Rev Neurother 2005; 5: 721-7.
    • (2005) Expert Rev Neurother , vol.5 , pp. 721-7
    • Sipe, J.C.1
  • 11
    • 0026799508 scopus 로고
    • Cladribine (2-chlorodeoxyadenosine)
    • Beutler E. Cladribine (2-chlorodeoxyadenosine). Lancet 1992; 340: 952-6.
    • (1992) Lancet , vol.340 , pp. 952-6
    • Beutler, E.1
  • 12
    • 0028264426 scopus 로고
    • Cladribine in treat- ment of chronic progressive multiple sclerosis
    • Sipe JC, Romine JS, Koziol JA, et al. Cladribine in treat- ment of chronic progressive multiple sclerosis. Lancet 1994; 344: 9-13.
    • (1994) Lancet , vol.344 , pp. 9-13
    • Sipe, J.C.1    Romine, J.S.2    Koziol, J.A.3
  • 13
    • 0029983154 scopus 로고    scopus 로고
    • The treatment of chronic progressive multiple sclerosis with cladribine
    • Beutler E, Sipe JC, Romine JS, et al. The treatment of chronic progressive multiple sclerosis with cladribine. Proc Natl Acad Sci USA 1996; 93: 1716-20.
    • (1996) Proc Natl Acad Sci USA , vol.93 , pp. 1716-20
    • Beutler, E.1    Sipe, J.C.2    Romine, J.S.3
  • 14
    • 0032908474 scopus 로고    scopus 로고
    • A double-blind, placebo- controlled, randomized trial of cladribine in relapsing-remitting multiple sclerosis
    • Romine JS, Sipe JC, Koziol JA, et al. A double-blind, placebo- controlled, randomized trial of cladribine in relapsing-remitting multiple sclerosis. Proc Assoc Am Physicians 1999; 111: 35-44.
    • (1999) Proc Assoc Am Physicians , vol.111 , pp. 35-44
    • Romine, J.S.1    Sipe, J.C.2    Koziol, J.A.3
  • 15
    • 0034642247 scopus 로고    scopus 로고
    • Whole brain vol- ume changes in patients with progressive MS treated with cladribine
    • Filippi M, Rovaris M, Iannucci G, et al. Whole brain vol- ume changes in patients with progressive MS treated with cladribine. Neurology 2000; 55: 1714-8.
    • (2000) Neurology , vol.55 , pp. 1714-8
    • Filippi, M.1    Rovaris, M.2    Iannucci, G.3
  • 16
    • 0034194016 scopus 로고    scopus 로고
    • The effect of cladribine on T(1) 'black hole' changes in progressive MS
    • Filippi M, Rovaris M, Rice GP, et al. The effect of cladribine on T(1) 'black hole' changes in progressive MS. J Neurol Sci 2000; 176: 42-4.
    • (2000) J Neurol Sci , vol.176 , pp. 42-4
    • Filippi, M.1    Rovaris, M.2    Rice, G.P.3
  • 17
    • 0034646216 scopus 로고    scopus 로고
    • Cladribine and progressive MS: Clinical and MRI outcomes of a multicenter controlled trial
    • Cladribine MRI Study Group
    • Rice GP, Filippi M, Comi G. Cladribine and progressive MS: clinical and MRI outcomes of a multicenter controlled trial. Cladribine MRI Study Group. Neurology 2000; 54: 1145-55.
    • (2000) Neurology , vol.54 , pp. 1145-55
    • Rice, G.P.1    Filippi, M.2    Comi, G.3
  • 18
    • 54149116366 scopus 로고    scopus 로고
    • Efficacy and safety of oral fumarate in patients with relapsing-remitting multiple sclerosis: A multicentre, randomised, double-blind, placebo-controlled phase IIb study
    • Kappos L, Gold R, Miller DH, et al. Efficacy and safety of oral fumarate in patients with relapsing-remitting multiple sclerosis: a multicentre, randomised, double-blind, placebo-controlled phase IIb study. Lancet 2008; 372: 1463-72.
    • (2008) Lancet , vol.372 , pp. 1463-72
    • Kappos, L.1    Gold, R.2    Miller, D.H.3
  • 19
    • 45249107267 scopus 로고    scopus 로고
    • Effect of laquinimod on MRI-monitored disease activity in patients with relapsing-remitting multiple sclerosis: A multicentre, randomised, double-blind, placebo-controlled phase IIb study
    • Comi G, Pulizzi A, Rovaris M, et al. Effect of laquinimod on MRI-monitored disease activity in patients with relapsing-remitting multiple sclerosis: a multicentre, randomised, double-blind, placebo-controlled phase IIb study. Lancet 2008; 371: 2085-92.
    • (2008) Lancet , vol.371 , pp. 2085-92
    • Comi, G.1    Pulizzi, A.2    Rovaris, M.3
  • 20
    • 33645799680 scopus 로고    scopus 로고
    • A phase II study of the safety and efficacy of teriflunomide in multiple sclerosis with relapses
    • O'Connor PW, Li D, Freedman MS, et al. A phase II study of the safety and efficacy of teriflunomide in multiple sclerosis with relapses. Neurology 2006; 66: 894-900.
    • (2006) Neurology , vol.66 , pp. 894-900
    • O'Connor, P.W.1    Li, D.2    Freedman, M.S.3
  • 21
    • 0027418515 scopus 로고
    • Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. I. Clinical results of a multicenter, randomized, double-blind, placebo-controlled trial
    • The IFN-beta Multiple Sclerosis Study Group
    • The IFN-beta Multiple Sclerosis Study Group. Interferon beta-1b is effective in relapsing-remitting multiple sclerosis: I. Clinical results of a multicenter, randomized, double-blind, placebo-controlled trial. Neurology 1993; 43: 655-61.
    • (1993) Neurology , vol.43 , pp. 655-61
  • 22
    • 0008678962 scopus 로고    scopus 로고
    • Intramuscular interferon beta-la for disease progression in relapsing multiple sclerosis
    • for the Multi- ple Sclerosis Collaborative Research Group (MSCRG)
    • Jacobs LD, Cookfair DL, Rudick RA, et al., for the Multi- ple Sclerosis Collaborative Research Group (MSCRG). Intramuscular interferon beta-la for disease progression in relapsing multiple sclerosis. Ann Neurol 1996; 39: 285-94.
    • (1996) Ann Neurol , vol.39 , pp. 285-94
    • Jacobs, L.D.1    Cookfair, D.L.2    Rudick, R.A.3
  • 23
    • 74249110620 scopus 로고    scopus 로고
    • Oral laquinimod in patients with relapsing-remitting multiple sclerosis: 9-month double-blind active extension of the multiple-center, randomized, double-blind, parallel-group placebo-controlled study [abstract no. P31]
    • for the LAQ/5062 Clinical Advisory Board and Study Group
    • Comi G, Abramsky O, Arbizu T, et al., for the LAQ/5062 Clinical Advisory Board and Study Group. Oral laquinimod in patients with relapsing-remitting multiple sclerosis: 9-month double-blind active extension of the multiple-center, randomized, double-blind, parallel-group placebo-controlled study [abstract no. P31]. Mult Scler 2008; 14 (1 Suppl.): S37-8.
    • (2008) Mult Scler , vol.14 , Issue.1 SUPPL.
    • Comi, G.1    Abramsky, O.2    Arbizu, T.3
  • 24
    • 43449108927 scopus 로고    scopus 로고
    • Leustatin® (cladribine) Raritan (NJ): Centocor Ortho Biotech
    • Leustatin® (cladribine): US prescribing information. Rari- tan (NJ): Centocor Ortho Biotech, 2007.
    • (2007) US Prescribing Information
  • 25
    • 0037214931 scopus 로고    scopus 로고
    • Phase II study of cladribine and cyclophosphamide in patients with chronic lymphocytic leukemia and prolymphocytic leukemia
    • Montillo M, Tedeschi A, O'Brien S, et al. Phase II study of cladribine and cyclophosphamide in patients with chronic lymphocytic leukemia and prolymphocytic leukemia. Cancer 2003; 97: 114-20.
    • (2003) Cancer , vol.97 , pp. 114-20
    • Montillo, M.1    Tedeschi, A.2    O'Brien, S.3
  • 26
    • 77957184066 scopus 로고
    • Progressive multi- focal leukoencephalopathy: A hitherto unrecognized complication of chronic lymphatic leukemia and Hodgkin's disease
    • Astrom K, Mancall EL, Richardson EP. Progressive multi- focal leukoencephalopathy: a hitherto unrecognized complication of chronic lymphatic leukemia and Hodgkin's disease. Brain 1958; 81: 93-111.
    • (1958) Brain , vol.81 , pp. 93-111
    • Astrom, K.1    Mancall, E.L.2    Richardson, E.P.3
  • 27
    • 12344302306 scopus 로고    scopus 로고
    • FTY720: Mechanism of action and potential benefit in organ transplantation
    • Brinkmann V. FTY720: mechanism of action and potential benefit in organ transplantation. Yonsei Med J 2004; 45: 991-7.
    • (2004) Yonsei Med J , vol.45 , pp. 991-7
    • Brinkmann, V.1
  • 28
    • 1642580757 scopus 로고    scopus 로고
    • Lymphocyte egress from thymus and peripheral lymphoid organs is dependent on S1P receptor 1
    • Matloubian M, Lo CG, Cinamon G, et al. Lymphocyte egress from thymus and peripheral lymphoid organs is dependent on S1P receptor 1. Nature 2004; 427: 355-60.
    • (2004) Nature , vol.427 , pp. 355-60
    • Matloubian, M.1    Lo, C.G.2    Cinamon, G.3
  • 29
    • 17644365138 scopus 로고    scopus 로고
    • Chemokines, sphingosine-1-phosphate, and cell migration in secondary lymphoid organs
    • Cyster JG. Chemokines, sphingosine-1-phosphate, and cell migration in secondary lymphoid organs. Annu Rev Immunol 2005; 23: 127-59.
    • (2005) Annu Rev Immunol , vol.23 , pp. 127-59
    • Cyster, J.G.1
  • 30
    • 3142709457 scopus 로고    scopus 로고
    • FTY720-enhanced T cell homing is dependent on CCR2, CCR5, CCR7, and CXCR4: Evidence for distinct chemokine compartments
    • Yopp AC, Fu S, Honig SM, et al. FTY720-enhanced T cell homing is dependent on CCR2, CCR5, CCR7, and CXCR4: evidence for distinct chemokine compartments. J Immunol 2004; 173: 855-65.
    • (2004) J Immunol , vol.173 , pp. 855-65
    • Yopp, A.C.1    Fu, S.2    Honig, S.M.3
  • 31
    • 0037379202 scopus 로고    scopus 로고
    • Amelioration of experimental autoimmune encephalomyelitis in Lewis rats by FTY720 treatment
    • Fujino M, Funeshima N, Kitazawa Y, et al. Amelioration of experimental autoimmune encephalomyelitis in Lewis rats by FTY720 treatment. J Pharmacol Exp Ther 2003; 305: 70-7.
    • (2003) J Pharmacol Exp Ther , vol.305 , pp. 70-7
    • Fujino, M.1    Funeshima, N.2    Kitazawa, Y.3
  • 32
    • 3042750654 scopus 로고    scopus 로고
    • Predictability of FTY720 efficacy in experimental autoimmune encephalomyelitis by in vivo macrophage tracking: Clinical implications for ultrasmall superparamagnetic iron oxide-enhanced magnetic resonance imaging
    • Rausch M, Hiestand P, Foster CA, et al. Predictability of FTY720 efficacy in experimental autoimmune encephalomyelitis by in vivo macrophage tracking: clinical implications for ultrasmall superparamagnetic iron oxide-enhanced magnetic resonance imaging. J Magn Reson Imaging 2004; 20: 16-24.
    • (2004) J Magn Reson Imaging , vol.20 , pp. 16-24
    • Rausch, M.1    Hiestand, P.2    Foster, C.A.3
  • 33
    • 3242683494 scopus 로고    scopus 로고
    • Sphingosine 1-phosphate receptor agonists attenuate relapsing-remitting experimental autoimmune encephalitis in SJL mice
    • Webb M, Tham CS, Lin FF, et al. Sphingosine 1-phosphate receptor agonists attenuate relapsing-remitting experimental autoimmune encephalitis in SJL mice. J Neuro-immunol 2004; 153: 108-21.
    • (2004) J Neuroimmunol , vol.153 , pp. 108-21
    • Webb, M.1    Tham, C.S.2    Lin, F.F.3
  • 34
    • 0037077308 scopus 로고    scopus 로고
    • The immune modulator FTY720 targets sphingosine 1-phosphate receptors
    • Brinkmann V, Davis MD, Heise CE, et al. The immune modulator FTY720 targets sphingosine 1-phosphate receptors. J Biol Chem 2002; 277: 21453-7.
    • (2002) J Biol Chem , vol.277 , pp. 21453-7
    • Brinkmann, V.1    Davis, M.D.2    Heise, C.E.3
  • 35
    • 77953211778 scopus 로고    scopus 로고
    • The impact of fingolimod (FTY720) in neuroimmunologic diseases: Mechanisms beyond im-munomodulation
    • Haghikia A, Gold R. The impact of fingolimod (FTY720) in neuroimmunologic diseases: mechanisms beyond im-munomodulation. Am J Pathol 2010; 176: 2599-601.
    • (2010) Am J Pathol , vol.176 , pp. 2599-601
    • Haghikia, A.1    Gold, R.2
  • 36
    • 77951479603 scopus 로고    scopus 로고
    • Oral fingolimod (FTY720) inhibits ongoing CNS autoimmunity and promotes recovery in mice with chronic experimental autoimmune encephalomyelitis [abstract no. P228]
    • Bernard F, Sablone M, Sansig G, et al. Oral fingolimod (FTY720) inhibits ongoing CNS autoimmunity and promotes recovery in mice with chronic experimental autoimmune encephalomyelitis [abstract no. P228]. Mult Scler 2009; 15 Suppl. 2: S58.
    • (2009) Mult Scler , vol.15 , Issue.SUPPL. 2
    • Bernard, F.1    Sablone, M.2    Sansig, G.3
  • 37
    • 77955799815 scopus 로고    scopus 로고
    • Oral fingolimod (FTY720) for relapsing multiple sclerosis
    • Kappos L, Antel J, Comi G, et al. Oral fingolimod (FTY720) for relapsing multiple sclerosis. N Engl J Med 2006; 355: 1124-40.
    • (2006) N Engl J Med , vol.355 , pp. 1124-40
    • Kappos, L.1    Antel, J.2    Comi, G.3
  • 38
    • 63849147004 scopus 로고    scopus 로고
    • Oral fingolimod (FTY720) in multiple sclerosis: Two-year results of a phase II extension study
    • O'Connor P, Comi G, Montalban X, et al. Oral fingolimod (FTY720) in multiple sclerosis: two-year results of a phase II extension study. Neurology 2009; 72: 73-9.
    • (2009) Neurology , vol.72 , pp. 73-9
    • O'Connor, P.1    Comi, G.2    Montalban, X.3
  • 39
    • 76449120437 scopus 로고    scopus 로고
    • Phase II study of oral fin-golimod (FTY720) in multiple sclerosis: 3-year results
    • for the FTY720D2201 Study Group
    • Comi G, O'Connor P, Montalban X, et al., for the FTY720D2201 Study Group. Phase II study of oral fin-golimod (FTY720) in multiple sclerosis: 3-year results. Mult Scler 2010; 16: 197-207.
    • (2010) Mult Scler , vol.16 , pp. 197-207
    • Comi, G.1    O'Connor, P.2    Montalban, X.3
  • 40
  • 41
    • 78649820015 scopus 로고    scopus 로고
    • Efficacy of the selective S1P 1/5 modulator, BAF312, in established experimental autoimmune encephalomyelitis and redistribution of S1P1 and S1P5 in the inflamed human CNS tissue [poster no. P858]
    • Oct 13-16; Gothenburg
    • Seabrook TJ, Smith P, Schweitzer A, et al. Efficacy of the selective S1P 1/5 modulator, BAF312, in established experimental autoimmune encephalomyelitis and redistribution of S1P1 and S1P5 in the inflamed human CNS tissue [poster no. P858]. 26th Congress of the European Committee for the Treatment and Research in Multiple Sclerosis; 2010 Oct 13-16; Gothenburg.
    • (2010) 26th Congress of the European Committee for the Treatment and Research in Multiple Sclerosis
    • Seabrook, T.J.1    Smith, P.2    Schweitzer, A.3
  • 42
    • 78649806040 scopus 로고    scopus 로고
    • A phase i study to evaluate safety tolerability and pharmacological properties of a selective sphingosine-1-phosphate (S1P) receptor agonist ONO-4641 in patients with multiple sclerosis [poster no. P991]
    • ONO-4641 Study Group Oct 13-16; Gothenburg
    • Kasper LH, Due BR, ONO-4641 Study Group. A phase I study to evaluate safety, tolerability and pharmacological properties of a selective sphingosine-1-phosphate (S1P) receptor agonist ONO-4641 in patients with multiple sclerosis [poster no. P991]. 26th Congress of the European Committee for the Treatment and Research in Multiple Sclerosis; 2010 Oct 13-16; Gothenburg.
    • (2010) 26th Congress of the European Committee for the Treatment and Research in Multiple Sclerosis
    • Kasper, L.H.1    Due, B.R.2
  • 43
    • 54349101744 scopus 로고    scopus 로고
    • Identification and devel- opment of new therapeutics for multiple sclerosis
    • Linker RA, Kieseier BC, Gold R. Identification and devel- opment of new therapeutics for multiple sclerosis. Trends Pharmacol Sci 2008; 29: 558-65.
    • (2008) Trends Pharmacol Sci , vol.29 , pp. 558-65
    • Linker, R.A.1    Kieseier, B.C.2    Gold, R.3
  • 44
    • 41549092261 scopus 로고    scopus 로고
    • Rasagiline in treatment of Parkin- son's disease
    • Nayak L, Henchcliffe C. Rasagiline in treatment of Parkin- son's disease. Neuropsychiatr Dis Treat 2008; 4: 11-20.
    • (2008) Neuropsychiatr Dis Treat , vol.4 , pp. 11-20
    • Nayak, L.1    Henchcliffe, C.2
  • 45
    • 33744819999 scopus 로고    scopus 로고
    • Antioxidants in multiple sclerosis: Do they have a role in therapy?
    • Carlson NG, Rose JW. Antioxidants in multiple sclerosis: do they have a role in therapy? CNS Drugs 2006; 20: 433-41.
    • (2006) CNS Drugs , vol.20 , pp. 433-41
    • Carlson, N.G.1    Rose, J.W.2
  • 46
    • 74049120922 scopus 로고    scopus 로고
    • New oral drugs for multiple sclerosis
    • Gasperini C, Ruggieri S. New oral drugs for multiple sclerosis. Neurol Sci 2009; 30 Suppl. 2: S179-83.
    • (2009) Neurol Sci , vol.30 , Issue.SUPPL. 2
    • Gasperini, C.1    Ruggieri, S.2
  • 47
    • 47849083585 scopus 로고    scopus 로고
    • Nrf2 signaling: An adaptive re- sponse pathway for protection against environmental toxic insults
    • Osburn WO, Kensler TW. Nrf2 signaling: an adaptive re- sponse pathway for protection against environmental toxic insults. Mutat Res 2008; 659: 31-9.
    • (2008) Mutat Res , vol.659 , pp. 31-9
    • Osburn, W.O.1    Kensler, T.W.2
  • 48
    • 58649100237 scopus 로고    scopus 로고
    • Nrf2- regulated glutathione recycling independent of biosynthesis is critical for cell survival during oxidative stress
    • Harveya CJ, Thimmulappaa RK, Singha A, et al. Nrf2- regulated glutathione recycling independent of biosynthesis is critical for cell survival during oxidative stress. Free Radic Biol Med 2009; 46: 443-53.
    • (2009) Free Radic Biol Med , vol.46 , pp. 443-53
    • Harveya, C.J.1    Thimmulappaa, R.K.2    Singha, A.3
  • 49
    • 33846264538 scopus 로고    scopus 로고
    • Nrf2-deficient mice have an increased susceptibility to dextran sulfate sodium-induced colitis
    • Khor T, Huang M, Kwon K, et al. Nrf2-deficient mice have an increased susceptibility to dextran sulfate sodium-induced colitis. Cancer Res 2006; 66: 11580-4.
    • (2006) Cancer Res , vol.66 , pp. 11580-4
    • Khor, T.1    Huang, M.2    Kwon, K.3
  • 50
    • 0038146898 scopus 로고    scopus 로고
    • Identification of the NF- E2-related factor-2-dependent genes conferring protection against oxidative stress in primary cortical astrocytes using oligonucleotide microarray analysis
    • Lee JM, Calkins MJ, Chan K, et al. Identification of the NF- E2-related factor-2-dependent genes conferring protection against oxidative stress in primary cortical astrocytes using oligonucleotide microarray analysis. J Biol Chem 2003; 278: 12029-38.
    • (2003) J Biol Chem , vol.278 , pp. 12029-38
    • Lee, J.M.1    Calkins, M.J.2    Chan, K.3
  • 51
    • 0141621061 scopus 로고    scopus 로고
    • NF-E2-related factor- 2 mediates neuroprotection against mitochondrial complex i inhibitors and increased concentrations of intracellular calcium in primary cortical neurons
    • Lee JM, Shih AY, Murphy TH, et al. NF-E2-related factor- 2 mediates neuroprotection against mitochondrial complex I inhibitors and increased concentrations of intracellular calcium in primary cortical neurons. J Biol Chem 2003; 278: 37948-56.
    • (2003) J Biol Chem , vol.278 , pp. 37948-56
    • Lee, J.M.1    Shih, A.Y.2    Murphy, T.H.3
  • 52
    • 57649213538 scopus 로고    scopus 로고
    • The Nrf2-ARE pathway: An indicator and modulator of oxidative stress in neurodegeneration
    • Johnson JA, Johnson DA, Kraft AD, et al. The Nrf2-ARE pathway: an indicator and modulator of oxidative stress in neurodegeneration. Ann N Y Acad Sci 2008; 1147: 61-9.
    • (2008) Ann N y Acad Sci , vol.1147 , pp. 61-9
    • Johnson, J.A.1    Johnson, D.A.2    Kraft, A.D.3
  • 53
    • 20744440945 scopus 로고    scopus 로고
    • Induction of the Nrf2-driven antioxidant response confers neuroprotection during mitochondrial stress in vivo
    • Shih AY, Imbeault S, Barakauskas V, et al. Induction of the Nrf2-driven antioxidant response confers neuroprotection during mitochondrial stress in vivo. J Biol Chem 2005; 280: 22925-36.
    • (2005) J Biol Chem , vol.280 , pp. 22925-36
    • Shih, A.Y.1    Imbeault, S.2    Barakauskas, V.3
  • 54
    • 51649088304 scopus 로고    scopus 로고
    • Activation of Nrf2 and modulation of disease progression in EAE models by BG-12 (dimethyl fumarate) suggests a novel mechanism of action combining anti-inflammatory and neuroprotec-tive modalities [abstract no. P503]
    • Lukashev M, Zeng W, Goelz S, et al. Activation of Nrf2 and modulation of disease progression in EAE models by BG-12 (dimethyl fumarate) suggests a novel mechanism of action combining anti-inflammatory and neuroprotec-tive modalities [abstract no. P503]. Mult Scler 2007; 13 (2 Suppl.): S149.
    • (2007) Mult Scler , vol.13 , Issue.2 SUPPL.
    • Lukashev, M.1    Zeng, W.2    Goelz, S.3
  • 55
    • 33745162188 scopus 로고    scopus 로고
    • Fumaric acid esters are effective in chronic experimental autoimmune encephalo-myelitis and suppress macrophage infiltration
    • Schilling S, Goelz S, Linker R, et al. Fumaric acid esters are effective in chronic experimental autoimmune encephalo-myelitis and suppress macrophage infiltration. Clin Exp Immunol 2006; 145: 101-7.
    • (2006) Clin Exp Immunol , vol.145 , pp. 101-7
    • Schilling, S.1    Goelz, S.2    Linker, R.3
  • 56
    • 33745051595 scopus 로고    scopus 로고
    • Oral fumaric acid esters for the treatment of active multiple sclerosis: An open-label, baseline-controlled pilot study
    • Schimrigk S, Brune N, Hellwig K, et al. Oral fumaric acid esters for the treatment of active multiple sclerosis: an open-label, baseline-controlled pilot study. Eur J Neurol 2006; 13: 604-10.
    • (2006) Eur J Neurol , vol.13 , pp. 604-10
    • Schimrigk, S.1    Brune, N.2    Hellwig, K.3
  • 57
    • 78649508546 scopus 로고    scopus 로고
    • The effect of BG00012 on conversion of gadolinium-enhancing lesions to T1-hypointense lesions [abstract no. P459]
    • MacManus DG, Miller DH, Kappos L, et al. The effect of BG00012 on conversion of gadolinium-enhancing lesions to T1-hypointense lesions [abstract no. P459]. Mult Scler 2008; 14 Suppl. 2: S163.
    • (2008) Mult Scler , vol.14 , Issue.SUPPL. 2
    • MacManus, D.G.1    Miller, D.H.2    Kappos, L.3
  • 58
    • 0042413498 scopus 로고    scopus 로고
    • Long-term safety aspects of systemic therapy with fumaric acid esters in severe psoriasis
    • Hoefnagel JJ, Thio HB, Willemze R, et al. Long-term safety aspects of systemic therapy with fumaric acid esters in severe psoriasis. Br J Dermatol 2003; 149: 363-9.
    • (2003) Br J Dermatol , vol.149 , pp. 363-9
    • Hoefnagel, J.J.1    Thio, H.B.2    Willemze, R.3
  • 59
    • 34249693512 scopus 로고    scopus 로고
    • German evidence-based guidelines for the treatment of psoriasis vulgaris (short version)
    • Nast A, Kopp I, Augustin M, et al. German evidence-based guidelines for the treatment of psoriasis vulgaris (short version). Arch Dermatol Res 2007; 299: 111-38.
    • (2007) Arch Dermatol Res , vol.299 , pp. 111-38
    • Nast, A.1    Kopp, I.2    Augustin, M.3
  • 60
    • 0029838040 scopus 로고    scopus 로고
    • Linomide reduces the rate of active lesions in relapsing-remitting multiple sclerosis
    • Andersen O, Lycke J, Tollesson PO, et al. Linomide reduces the rate of active lesions in relapsing-remitting multiple sclerosis. Neurology 1996; 47: 895-900.
    • (1996) Neurology , vol.47 , pp. 895-900
    • Andersen, O.1    Lycke, J.2    Tollesson, P.O.3
  • 61
    • 0029832923 scopus 로고    scopus 로고
    • Treatment of secondary progressive multiple sclerosis with the immuno-modulator linomide: A double-blind, placebo-controlled pilot study with monthly magnetic resonance imaging evaluation
    • Karussis DM, Meiner Z, Lehmann D, et al. Treatment of secondary progressive multiple sclerosis with the immuno-modulator linomide: a double-blind, placebo-controlled pilot study with monthly magnetic resonance imaging evaluation. Neurology 1996; 47: 341-6.
    • (1996) Neurology , vol.47 , pp. 341-6
    • Karussis, D.M.1    Meiner, Z.2    Lehmann, D.3
  • 62
    • 0034624942 scopus 로고    scopus 로고
    • Linomide in relapsing and secondary progressive MS: Part I. Trial design and clinical results
    • North American Linomide Investigators
    • Noseworthy JH, Wolinsky JS, Lublin FD, et al. Linomide in relapsing and secondary progressive MS: part I. Trial design and clinical results. North American Linomide Investigators. Neurology 2000; 54: 1726-33.
    • (2000) Neurology , vol.54 , pp. 1726-33
    • Noseworthy, J.H.1    Wolinsky, J.S.2    Lublin, F.D.3
  • 63
    • 0036710356 scopus 로고    scopus 로고
    • The new orally active immunoregulator laquinimod (ABR-215062) effectively inhibits development and relapses of experimental autoimmune encephalomyelitis
    • Brunmark C, Runstrom A, Ohlsson L, et al. The new orally active immunoregulator laquinimod (ABR-215062) effectively inhibits development and relapses of experimental autoimmune encephalomyelitis. J Neuroimmunol 2002; 130: 163-72.
    • (2002) J Neuroimmunol , vol.130 , pp. 163-72
    • Brunmark, C.1    Runstrom, A.2    Ohlsson, L.3
  • 64
    • 4744340401 scopus 로고    scopus 로고
    • Laquinimod (ABR- 215062) suppresses the development of experimental autoimmune encephalomyelitis, modulates the Th1/Th2 balance and induces the Th3 cytokine TGF-beta in Lewis rats
    • Yang JS, Xu LY, Xiao BG, et al. Laquinimod (ABR- 215062) suppresses the development of experimental autoimmune encephalomyelitis, modulates the Th1/Th2 balance and induces the Th3 cytokine TGF-beta in Lewis rats. J Neuroimmunol 2004; 156: 3-9.
    • (2004) J Neuroimmunol , vol.156 , pp. 3-9
    • Yang, J.S.1    Xu, L.Y.2    Xiao, B.G.3
  • 65
    • 77951454321 scopus 로고    scopus 로고
    • Laquinimod induces up-regulation of neurotrophins in serum of patients with relapsing-remitting multiple sclerosis [abstract no. P783]
    • Linker RA, Thone J, Comi G, et al. Laquinimod induces up-regulation of neurotrophins in serum of patients with relapsing-remitting multiple sclerosis [abstract no. P783]. Mult Scler 2009; 15 (9 Suppl. 2): S237.
    • (2009) Mult Scler , vol.15 , Issue.9 SUPPL. 2
    • Linker, R.A.1    Thone, J.2    Comi, G.3
  • 67
    • 33644936033 scopus 로고    scopus 로고
    • Inhibition of the development of chronic experimental autoimmune en-cephalomyelitis by laquinimod (ABR-215062) in IFN-beta k.o. and wild type mice
    • Runstrom A, Leanderson T, Ohlsson L, et al. Inhibition of the development of chronic experimental autoimmune en-cephalomyelitis by laquinimod (ABR-215062) in IFN-beta k.o. and wild type mice. J Neuroimmunol 2006; 173: 69-78.
    • (2006) J Neuroimmunol , vol.173 , pp. 69-78
    • Runstrom, A.1    Leanderson, T.2    Ohlsson, L.3
  • 68
    • 15244353263 scopus 로고    scopus 로고
    • Treatment with laquinimod reduces development of active MRI lesions in relapsing MS
    • Polman C, Barkhof F, Sandberg-Wollheim M, et al. Treat- ment with laquinimod reduces development of active MRI lesions in relapsing MS. Neurology 2005; 64: 987-91.
    • (2005) Neurology , vol.64 , pp. 987-91
    • Polman, C.1    Barkhof, F.2    Sandberg-Wollheim, M.3
  • 69
    • 0034840913 scopus 로고    scopus 로고
    • Suppression of ex- perimental autoimmune neuritis by leflunomide
    • Korn T, Toyka K, Hartung HP, et al. Suppression of ex- perimental autoimmune neuritis by leflunomide. Brain 2001; 124 (Pt 9): 1791-802.
    • (2001) Brain , vol.124 , Issue.PART 9 , pp. 1791-802
    • Korn, T.1    Toyka, K.2    Hartung, H.P.3
  • 70
    • 7644223637 scopus 로고    scopus 로고
    • Modulation of effector cell functions in experimental autoimmune encephalo-myelitis by leflunomide: Mechanisms independent of pyr-imidine depletion
    • Korn T, Magnus T, Toyka K, et al. Modulation of effector cell functions in experimental autoimmune encephalo-myelitis by leflunomide: mechanisms independent of pyr-imidine depletion. J Leukoc Biol 2004; 76: 50-60.
    • (2004) J Leukoc Biol , vol.76 , pp. 50-60
    • Korn, T.1    Magnus, T.2    Toyka, K.3
  • 71
    • 0032374063 scopus 로고    scopus 로고
    • Purification of human dihydro-orotate dehydrogenase and its inhibition by A77,1726, the active metabolite of leflunomide
    • Bruneau JM, Yea CM, Spinella-Jaegle S, et al. Purification of human dihydro-orotate dehydrogenase and its inhibition by A77 1726, the active metabolite of leflunomide. Biochem J 1998; 336 (Pt 2): 299-303.
    • (1998) Biochem J , vol.336 , Issue.PART 2 , pp. 299-303
    • Bruneau, J.M.1    Yea, C.M.2    Spinella-Jaegle, S.3
  • 72
    • 0029591467 scopus 로고
    • The immuno- suppressant leflunomide inhibits lymphocyte proliferation by inhibiting pyrimidine biosynthesis
    • Cherwinski HM, Cohn RG, Cheung P, et al. The immuno- suppressant leflunomide inhibits lymphocyte proliferation by inhibiting pyrimidine biosynthesis. J Pharmacol Exp Ther 1995; 275: 1043-9.
    • (1995) J Pharmacol Exp Ther , vol.275 , pp. 1043-9
    • Cherwinski, H.M.1    Cohn, R.G.2    Cheung, P.3
  • 73
    • 25444448197 scopus 로고    scopus 로고
    • Disruption of the interaction of T cells with antigen-presenting cells by the active leflunomide metabolite teriflunomide: Involvement of impaired integrin activation and immunologic synapse formation
    • Zeyda M, Poglitsch M, Geyeregger R, et al. Disruption of the interaction of T cells with antigen-presenting cells by the active leflunomide metabolite teriflunomide: involvement of impaired integrin activation and immunologic synapse formation. Arthritis Rheum 2005; 52: 2730-9.
    • (2005) Arthritis Rheum , vol.52 , pp. 2730-9
    • Zeyda, M.1    Poglitsch, M.2    Geyeregger, R.3
  • 74
    • 0033557695 scopus 로고    scopus 로고
    • Immunosuppressive leflunomide metabolite (A77 1726) blocks TNF-dependent nuclear factor-kappa B activation and gene expression
    • Manna SK, Aggarwal BB. Immunosuppressive leflunomide metabolite (A77 1726) blocks TNF-dependent nuclear factor-kappa B activation and gene expression. J Immunol 1999; 162: 2095-102.
    • (1999) J Immunol , vol.162 , pp. 2095-102
    • Manna, S.K.1    Aggarwal, B.B.2
  • 75
    • 62149096116 scopus 로고    scopus 로고
    • Teriflunomide re- duces behavioral, electrophysiological, and histopatholo-gical deficits in the Dark Agouti rat model of experimental autoimmune encephalomyelitis
    • Merrill JE, Hanak S, Pu SF, et al. Teriflunomide re- duces behavioral, electrophysiological, and histopatholo-gical deficits in the Dark Agouti rat model of experimental autoimmune encephalomyelitis. J Neurol 2009; 256: 89-103.
    • (2009) J Neurol , vol.256 , pp. 89-103
    • Merrill, J.E.1    Hanak, S.2    Pu, S.F.3
  • 76
    • 72649102197 scopus 로고    scopus 로고
    • The Will Rogers phenomenon: The effect of different diagnostic criteria
    • Sormani MP. The Will Rogers phenomenon: the effect of different diagnostic criteria. J Neurol Sci 2009; 287 Suppl. 1: S46-9.
    • (2009) J Neurol Sci , vol.287 , Issue.SUPPL. 1
    • Sormani, M.P.1
  • 77
    • 70449722872 scopus 로고    scopus 로고
    • Benefit-risk assessment of leflunomide: An appraisal of leflunomide in rheumatoid arthritis 10 years after licensing
    • Alcorn N, Saunders S, Madhok R. Benefit-risk assessment of leflunomide: an appraisal of leflunomide in rheumatoid arthritis 10 years after licensing. Drug Saf 2009; 32 (12): 1123-34
    • (2009) Drug Saf , vol.32 , Issue.12 , pp. 1123-34
    • Alcorn, N.1    Saunders, S.2    Madhok, R.3


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.